Document is current
Any future updates will be listed below
-
Authors
Iijima, Kazumoto
Sako, Mayumi
Horinouchi, Tomoko
Sakai, Tomoyuki
Yamamura, Tomohiko
Hamada, Riku
Ohtsuka, Yasufumi
Tanaka, Seiji
Kamei, Koichi
Tanaka, Ryojiro
Kano, Yuji
Kubota, Takuo
Shima, Yuko
Morohashi, Tamaki
Inaba, Aya
Fujinaga, Shuichiro
Oka, Masafumi
Kaito, Hiroshi
Konishi, Akihide
Nagano, China
Nakanishi, Koichi
Ishikura, Kenji
Ito, Shuichi
Nakamura, Hidefumi
Ghiggeri, Gian Marco
Mori, Rintaro
Omori, Takashi
Nozu, Kandai
,
,
Sakakibara, Nana
Kondo, Atsushi
Kitakado, Hideaki
Ueda, Chika
Sawai, Toshihiro
Yamamoto, Kazuna
Ichioka, Satoko
Masuda, Toshiki
Hataya, Hiroshi
Harada, Ryoko
Terano, Chikako
Mikami, Naoaki
Inoguchi, Tomohiro
Tomari, Kouki
Akamine, Keiji
Shirane, Shoichiro
Nada, Taishi
Kanamori, Toru
Kamae, Chikako
Inaguma, Yosuke
Takagi, Yuhi
Uchimura, Toru
,
Nozu, Kandai
Sako, Mayumi
,
Hattori, Motoshi
Tsuchida, Nao
Oba, Mari
-
Funding
Funding for this research was provided by:
Zenyaku Kogyo Co., Ltd. (JSKDC10)
- License Information
-
More Information
Article History
Received: 26 January 2025
Accepted: 8 September 2025
First Online: 10 October 2025
Declarations
:
: KIi reports a research grant for clinical trials and clinical research from Zenyaku Kogyo Co. Ltd. to his institution; consulting fees from Kyowa Kirin Co. Ltd., and Chugai Pharmaceutical Co., Ltd.; honoraria for manuscript writing from Zenyaku Kogyo Co. Ltd.; payment for expert testimony to my institution from Zenyaku Kogyo Co. Ltd.; and serves as a member of the advisory board of Kyowa Kirin Co. Ltd. and Chugai Pharmaceutical Co., Ltd.. MS reports grants for clinical trials and development promotion network from Japan Agency for Medical Research and Development; honoraria for lectures from Chugai Pharmaceutical Co., Ltd.; payment for expert testimony to her institution from Zenyaku Kogyo Co. Ltd.; and patent application of agent for treatment of pediatric hypozincemia. TH reports grants for clinical research from Sysmex Corporation, Otsuka Pharmaceutical Co. Ltd., and Zenyaku Kogyo Co. Ltd.. TS has nothing to disclose. TY has nothing to disclose. RH has nothing to disclose. YO reports honoraria for lectures from ARKRAY, Inc., Merck & Co., Inc., and SHIONOGI & CO., LTD.. ST has nothing to disclose. KK reports grants for clinical research from Public Foundation of Vaccination Research Center, Taiju Life Social Welfare Foundation, Chugai Pharmaceutical Co. Ltd., Teijin Pharma Ltd., Kyowa Kirin Co. Ltd., Taiho Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Co. Ltd., and Otsuka Pharmaceutical Co. Ltd.; honoraria for lectures from Terumo Co. Ltd., Baxter Ltd., Zenyaku Kogyo Co. Ltd.. RT has nothing to disclose. YK has nothing to disclose. TK has nothing to disclose. YS has nothing to disclose. TM has nothing to disclose. AI has nothing to disclose. SF has nothing to disclose. MO has nothing to disclose. HK has nothing to disclose. AK has nothing to disclose. CN has nothing to disclose. KNa reports consulting fees from Kyowa Kirin Co. Ltd. and AstraZeneca; honoraria for lectures from Kyowa Kirin Co. Ltd. and Novartis; and serves as the president of the Japanese Society for Pediatric Nephrology. KIs reports grants for clinical research from Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Novartis International AG, Japan Blood Products Organization, Teijin Pharma Limited, and Astellas Pharma Inc.; consulting fee from Chugai Pharmaceutical Co., Ltd.; honoraria for lectures from Zenyaku Kogyo Co. Ltd., Novartis International AG, and Teijin Pharma Limited. SI reports grants from Zenyaku Kogyo, Co., Ltd., Chuigai Pharmaceutical Co. Ltd., Astellas Pharma Inc., and Asahi Kasei Pharma Corporation; consulting fee from Zenyaku Kogyo Co. Ltd.; honoraria from Zenyaku Kogyo, Co., Ltd., Chuigai Pharmaceutical Co. Ltd., Novartis International AG, Asahi Kasei Pharma Corporation, and Astellas Pharma Inc.. HN reports grants for regulatory science on facilitating pediatric drug development from Japan Agency for Medical Research and Development; consulting fees from Tohoku University, Daiichi Sankyo Company, Limited, and Pfizer R&D Japan G.K.; Honoraria for lectures from Japan Pharmaceutical Manufacturers Association, Pfizer Global Supply Japan Inc., Bristol Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Northern Science Consulting Inc.; and serves as a member of advisory board of Taisho Pharmaceutical Holdings Co., Ltd. for drug development for diabetes, a member of advisory board of Sato Pharmaceutical Co., Ltd. for drug development for dermatology, Chairman of the Committee on Pharmaceutical Affairs of Japan Pediatric Society, and Chairman of the Steering Committee of Japan Society on Developmental Pharmacology and Therapeutics. GMG has nothing to disclose. RM has nothing to disclose. TO has nothing to disclose. KN reports a research grant for clinical trials and clinical research from Zenyaku Kogyo Co. Ltd. to his institution; consulting fees from Kyowa Kirin Co. Ltd., Toa Eiyo LTD., Zenyaku Kogyo Co. Ltd., and Taisho Pharmaceutical Co. Ltd.; honoraria for lectures from Ono Pharma, Astellas Pharma, Novo Nordisk Pharma, Alexion Pharma, Sumitomo Pharma, Sanofi, Otsuka Pharma, Daiichi Sankyo, and Miyarisan; and serves as a member of the advisory board of Kyowa Kirin Co. Ltd..
